Canary Capital Forms Delaware Trust for Potential Injective (INJ) Staking ETF Amid Regulatory Uncertainty

• Canary Capital has initiated the formation of a Delaware trust aimed at launching a staked Injective (INJ) token exchange-traded fund (ETF), signaling growing institutional interest in crypto staking products.

• This move aligns with a broader trend of asset managers exploring staking-based ETFs, which combine exposure to native blockchain tokens with yield generation through staking mechanisms.

• According to COINOTAG, “The establishment of the Canary Staked INJ ETF trust marks a strategic step towards integrating staking rewards into regulated investment vehicles, potentially expanding investor access to DeFi yield opportunities.”

Canary Capital’s Delaware trust formation for a staked Injective token ETF highlights emerging institutional demand for crypto staking exposure in regulated markets.

Delaware Trust Formation: A Strategic Step Toward a Staked Injective ETF

The creation of a Delaware trust is a conventional and critical initial phase for fund managers aiming to launch exchange-traded funds in the United States. Canary Capital’s recent filing for the “Canary Staked INJ ETF” trust reflects this established pathway, setting the groundwork for a potential ETF that would offer investors exposure to the Injective blockchain’s native token, INJ, combined with staking rewards.

While the trust formation itself does not guarantee the ETF’s approval or launch, it is a necessary legal and structural foundation. This approach has been mirrored by other crypto-focused ETFs, which often begin with Delaware trust filings before advancing to Securities and Exchange Commission (SEC) registration and approval processes.

Staking Exposure: A Growing Trend in Crypto ETFs

Staking-based ETFs represent an innovative category within the crypto investment landscape, enabling investors to benefit not only from price appreciation but also from the yield generated by locking tokens to support blockchain networks. Canary Capital’s initiative follows a similar filing made earlier this year for a Tron (TRX) staking ETF, demonstrating the firm’s strategic focus on yield-enhanced crypto products.

European asset manager 21Shares has already launched an Injective exchange-traded product that incorporates staking yields, indicating market appetite for such offerings. These products typically reinvest staking rewards, potentially enhancing returns over time while maintaining regulatory compliance.

Market Reaction and Injective Token Performance

The announcement of Canary Capital’s Delaware trust coincided with a notable 3.7% increase in the Injective token’s price over 24 hours, reflecting positive investor sentiment. Over the past week, INJ has appreciated by more than 10.5%, supported by increased on-chain activity and user engagement as reported by DappRadar.

Injective positions itself as a layer-1 blockchain specializing in artificial intelligence agents and the tokenization of real-world assets and stocks—sectors that continue to attract significant interest within the crypto ecosystem. This positioning may contribute to the token’s growing appeal among institutional and retail investors alike.

Regulatory Challenges Facing Crypto Staking ETFs

Despite enthusiasm from fund managers, the SEC has expressed reservations about the legal framework surrounding staking ETFs. Recent communications from the regulator to firms like REX Financial and Osprey Funds highlighted concerns that staking ETFs might not meet the definition of an investment company under current securities laws, potentially hindering their approval.

However, industry analysts remain cautiously optimistic. Bloomberg ETF analyst Eric Balchunas noted that legal teams are actively working to address these regulatory challenges, suggesting that solutions may be forthcoming to enable staking ETFs to enter the market under compliant structures.

Looking Ahead: The Future of Staked Crypto ETFs

The formation of the Canary Staked INJ ETF trust underscores a broader institutional push to integrate staking yields into regulated investment products. As regulatory clarity improves, investors could see a proliferation of staking ETFs that combine token exposure with yield generation, offering diversified risk-return profiles.

Market participants and observers should monitor forthcoming SEC filings and guidance closely, as these will shape the trajectory of staking ETFs and their accessibility to mainstream investors.

Conclusion

Canary Capital’s Delaware trust filing for a staked Injective token ETF represents a significant development in the evolving crypto ETF landscape. While regulatory hurdles remain, the initiative highlights growing institutional interest in staking-based products that offer both capital appreciation and yield. Investors seeking diversified crypto exposure should watch this space for further regulatory updates and potential product launches.